Wegovy vs Rybelsus: Full Comparison (2026)

How does Wegovy (Semaglutide) compare to Rybelsus (Semaglutide (oral))? We break down the weight loss data, pricing, side effects, and who each medication is best suited for.

Quick Answer

Wegovy (Semaglutide) and Rybelsus (Semaglutide (oral)) both work as GLP-1 receptor agonists but differ in formulation and dosing. Wegovy is FDA-approved for chronic weight management and cardiovascular risk reduction, while Rybelsus is approved for type 2 diabetes. Average weight loss: 15-17% of body weight (Wegovy) vs 5-10% of body weight (Rybelsus).

Side-by-Side Comparison

FeatureWegovyRybelsus
Active IngredientSemaglutideSemaglutide (oral)
MechanismGLP-1 receptor agonistGLP-1 receptor agonist
FDA Approved ForChronic weight management, Cardiovascular risk reductionType 2 diabetes
Doses0.25mg to 2.4mg (weekly injection), oral pill available3mg, 7mg, 14mg (daily oral tablet)
AdministrationWeekly subcutaneous injection or daily oral pillDaily oral tablet on empty stomach
Avg. Weight Loss15-17% of body weight5-10% of body weight
Monthly Price$1,349$936
Oral AvailableYesYes
Year Approved20212019

Prices reflect typical self-pay costs without insurance. Actual costs vary by pharmacy, location, and insurance plan. Last updated March 2026.

Which Produces More Weight Loss?

Based on clinical data, Wegovy produces more weight loss on average (15-17% of body weight) compared to Rybelsus (5-10% of body weight). Both work through similar mechanisms, but differences in formulation and dosing lead to different outcomes.

Wegovy
15-17% of body weight
average body weight loss

FDA-approved specifically for chronic weight management. Higher dose of semaglutide than Ozempic. Oral version launched January 2026.

Rybelsus
5-10% of body weight
average body weight loss

First oral GLP-1 medication. Lower doses than injectable semaglutide, resulting in less weight loss. Convenient for patients who prefer pills over injections.

Which Costs Less?

At list price, Rybelsus is the more affordable option at $936/month compared to $1,349/month for Wegovy. However, actual out-of-pocket costs depend heavily on your insurance plan. Wegovy with insurance: $25-$200/month typical copay. Rybelsus with insurance: $10-$150/month typical copay.

Wegovy
$1,349/month
With insurance: $25-$200/month typical copay

Oral pill: $149/month at lowest dose (launched Jan 2026)

Rybelsus
$936/month
With insurance: $10-$150/month typical copay

Manufacturer savings programs available

Side Effects Comparison

Both Wegovy (GLP-1 receptor agonist) and Rybelsus (GLP-1 receptor agonist) share similar gastrointestinal side effects, which are the most commonly reported:

  • Nausea (most common for both medications)
  • Diarrhea and vomiting
  • Constipation
  • Abdominal pain
  • Decreased appetite
  • Headache, fatigue, dizziness (less common)

Serious but rare side effects for both include pancreatitis, gallbladder problems, and kidney issues. Both carry warnings about medullary thyroid carcinoma risk based on animal studies. Always discuss your full medical history with your doctor before starting either medication.

Which Should You Choose?

The best choice depends on your diagnosis, insurance coverage, weight loss goals, and personal preferences. Here is our general guidance:

Choose Wegovy If
  • -Your primary goal is weight loss (FDA-approved indication)
  • -You prefer an oral option over injections
  • -You prefer a daily dosing routine
Choose Rybelsus If
  • -You have type 2 diabetes (on-label use, better insurance coverage)
  • -You prefer an oral option over injections
  • -Cost is a concern ($936/month at list price)
  • -You prefer a daily dosing routine

Find the Best GLP-1 Provider for You

Compare verified telehealth programs that prescribe Wegovy, Rybelsus, and other FDA-approved GLP-1 medications.

Frequently Asked Questions

Can I switch from Wegovy to Rybelsus?

Switching between Wegovy and Rybelsus is possible but requires medical supervision since they contain different active ingredients (Semaglutide vs Semaglutide (oral)). Your doctor will determine the appropriate starting dose and titration schedule for the new medication.

Which is better for weight loss: Wegovy or Rybelsus?

Clinical data suggests Wegovy produces more weight loss on average (15-17% of body weight) compared to Rybelsus (5-10% of body weight). However, individual results vary significantly based on dosing, diet, exercise, and metabolic factors.

Is Wegovy cheaper than Rybelsus?

At list price, Rybelsus ($936/month) is less expensive than Wegovy ($1,349/month). With insurance, costs vary significantly. Wegovy: $25-$200/month typical copay. Rybelsus: $10-$150/month typical copay.

Do Wegovy and Rybelsus have the same side effects?

Both medications share similar gastrointestinal side effects (nausea, diarrhea, vomiting, constipation) as these are common to GLP-1 receptor agonists. However, since they contain different active ingredients, there may be differences in frequency and severity. Discuss your medical history with your doctor to determine which has a better safety profile for you.

Does insurance cover Wegovy and Rybelsus?

Coverage varies by plan. Wegovy is FDA-approved for chronic weight management and cardiovascular risk reduction — insurance coverage is typically better for on-label use. Rybelsus is FDA-approved for type 2 diabetes. Check with your specific insurance plan and ask your doctor about prior authorization requirements.

Find Your GLP-1 Match — Free Quiz